Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Statement of Comprehensive Income
- Common-Size Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Solvency Ratios
- Common Stock Valuation Ratios
- Selected Financial Data since 2005
- Net Profit Margin since 2005
- Operating Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Short-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
A review of short-term operating activity ratios reveals several notable trends over the observed period. Generally, a declining trend is apparent in inventory management efficiency, while receivables management demonstrates more stability with a recent uptick. Payables management exhibits fluctuations, and working capital turnover shows a significant increase in later periods. The associated processing and conversion cycles reflect these underlying shifts.
- Inventory Turnover
- Inventory turnover consistently decreased from 2.83 to 0.98, indicating a lengthening of the time it takes to sell inventory. This suggests potential issues with inventory management, increasing holding costs, or declining sales relative to inventory levels. The rate of decline accelerated in the latter half of the period.
- Receivables Turnover
- Receivables turnover remained relatively stable between 6.15 and 6.31 for the first eight quarters. A decrease to 5.68 was observed, followed by a recovery to 6.85, and then a slight decline to 5.85. This suggests generally efficient collection of receivables, with a recent period of potential slowdown followed by improvement.
- Payables Turnover
- Payables turnover experienced significant volatility. It decreased from 5.52 to 3.55, increased to 8.23, then decreased again to 3.13 before fluctuating between 3.46 and 4.27. This suggests inconsistent management of payment terms with suppliers, potentially influenced by cash flow considerations or strategic negotiations.
- Working Capital Turnover
- Working capital turnover remained below 1.0 until the ninth quarter, indicating that the company was not generating sufficient revenue relative to its working capital. A substantial increase to 1.92 was observed, followed by a slight decline to 1.64. This suggests improved efficiency in utilizing working capital to generate sales, although the most recent period shows a moderation of this improvement.
- Processing & Conversion Cycles
- The average inventory processing period lengthened considerably, increasing from 129 days to 373 days, mirroring the decline in inventory turnover. The average receivable collection period remained relatively stable, fluctuating between 58 and 62 days, with a slight increase in recent periods. The operating cycle increased from 188 to 435 days, reflecting the combined effect of lengthening inventory and receivable cycles. The average payables payment period fluctuated, but generally increased, from 66 to 102 days. Consequently, the cash conversion cycle increased from 122 to 333 days, indicating a longer time to convert investments in inventory and receivables into cash.
In summary, the company experienced a notable slowdown in inventory turnover and a corresponding increase in the inventory processing period. While receivables management remained relatively stable, the significant fluctuations in payables turnover and the substantial increase in the cash conversion cycle warrant further investigation. The recent improvement in working capital turnover is a positive sign, but the overall trend suggests increasing challenges in efficiently managing short-term operating assets and liabilities.
Turnover Ratios
Average No. Days
Inventory Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||
| Cost of sales | |||||||||||||||||||||
| Inventories | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Inventory turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Inventory Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Inventory turnover
= (Cost of salesQ4 2025
+ Cost of salesQ3 2025
+ Cost of salesQ2 2025
+ Cost of salesQ1 2025)
÷ Inventories
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The inventory turnover ratio demonstrates a consistent downward trend over the observed period, spanning from March 31, 2022, to December 31, 2025. Initially, the ratio stood at 2.83, but it progressively declined to 0.98 by the end of the analyzed timeframe. This indicates a lengthening of the time it takes to sell inventory.
- Overall Trend
- A clear and sustained decline in inventory turnover is evident. The ratio decreased from 2.83 in the first quarter of 2022 to 0.98 in the final quarter of 2025, representing a significant reduction in efficiency regarding inventory management.
- Phased Changes
- The decline wasn't uniform. From March 2022 to December 2022, the ratio decreased from 2.83 to 2.35, representing a moderate initial decrease. The rate of decline accelerated between March 2023 and December 2024, falling from 2.06 to 1.27. The final phase, from March 2025 to December 2025, showed a continued, albeit slightly decelerated, decrease from 1.14 to 0.98.
- Cost of Sales and Inventory Relationship
- While cost of sales generally increased over the period, inventories increased at a faster rate. This disparity is the primary driver of the declining inventory turnover. The increase in inventory levels, coupled with a comparatively smaller increase in cost of sales, suggests a build-up of inventory that is not being sold as quickly.
- Recent Performance
- The most recent quarterly values (September 30, 2025, and December 31, 2025) show a ratio of 0.99 and 0.98 respectively. These values indicate that, on average, inventory is only being sold less than once per year. This is a substantial decrease from the initial ratio and warrants further investigation.
The consistent decrease in inventory turnover suggests potential issues with inventory management, demand forecasting, or product obsolescence. Further analysis is recommended to determine the underlying causes and implement appropriate corrective actions.
Receivables Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||
| Revenues | |||||||||||||||||||||
| Accounts receivable, net | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Receivables turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Receivables Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Receivables turnover
= (RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025)
÷ Accounts receivable, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The receivables turnover ratio exhibits a generally stable pattern over the observed period, with some fluctuations. Initially, the ratio demonstrates a slight increasing trend from March 2022 to September 2022, followed by a period of relative stability through December 2022. A noticeable decrease is then observed in March 2023, before recovering somewhat in subsequent quarters.
- Overall Trend
- From March 2022 through December 2022, the receivables turnover ratio remained relatively consistent, fluctuating between 6.15 and 6.31. A dip occurred in March 2023 to 5.95, representing the lowest point in the analyzed timeframe. The ratio then showed some recovery, peaking at 6.85 in December 2023, before declining again to 5.85 by December 2025.
- Short-Term Fluctuations
- A minor increase in the ratio is apparent from March 2022 (6.15) to September 2022 (6.28). This suggests a slightly improved efficiency in collecting receivables during this period. The subsequent decline to 5.95 in March 2023 warrants further investigation, potentially indicating a slowdown in collections or a change in credit terms. The increase to 6.85 in December 2023 is a significant positive movement, but this was not sustained, as the ratio decreased in the following periods.
- Recent Performance
- The most recent quarters show a downward trend in the receivables turnover ratio. From September 2024 (6.07) to December 2025 (5.85), the ratio decreased. This could indicate a lengthening of the collection period or a potential increase in the risk of bad debts. The ratio in December 2025 is the second lowest observed during the entire period.
The observed fluctuations in the receivables turnover ratio, particularly the recent decline, suggest a need for continued monitoring. Further analysis, potentially including days sales outstanding and a review of credit policies, would be beneficial to understand the underlying drivers of these changes.
Payables Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||
| Cost of sales | |||||||||||||||||||||
| Accounts payable | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Payables turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Payables Turnover, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Payables turnover
= (Cost of salesQ4 2025
+ Cost of salesQ3 2025
+ Cost of salesQ2 2025
+ Cost of salesQ1 2025)
÷ Accounts payable
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The accounts payable turnover ratio exhibits fluctuations over the observed period, spanning from March 31, 2022, to December 31, 2025. Initially, the ratio demonstrates a decline from 5.52 to 5.01 in the first two quarters, followed by a substantial increase to 8.23 in the subsequent quarter. A significant drop is then observed to 3.55, before stabilizing in a relatively narrow range between 3.13 and 4.27 for the following eight quarters. The final two quarters show a slight increase to 3.83 and then a decrease to 3.58.
- Initial Decline and Subsequent Rebound (Mar 31, 2022 – Sep 30, 2022)
- The initial decrease in the payables turnover ratio suggests a potential lengthening of the time taken to settle outstanding obligations to suppliers. However, this is quickly reversed with a notable increase, indicating a faster rate of payment. This could be attributed to strategic inventory management or changes in supplier credit terms.
- Period of Relative Stability (Dec 31, 2022 – Sep 30, 2024)
- From the end of 2022 through September 2024, the ratio remains within a constrained band. This suggests a consistent approach to managing accounts payable and maintaining a relatively stable relationship with suppliers. The fluctuations within this period are minor and do not indicate a significant shift in payment practices.
- Recent Fluctuations (Mar 31, 2025 – Dec 31, 2025)
- The final two quarters show a slight increase followed by a decrease in the ratio. While the change is not substantial, it warrants monitoring to determine if it signals a developing trend. This could be influenced by seasonal variations in purchasing activity or evolving supplier arrangements.
- Correlation with Cost of Sales
- A review of the cost of sales alongside the payables turnover ratio reveals a general upward trend in cost of sales throughout the period. The payables turnover ratio does not consistently correlate with the cost of sales. For example, cost of sales increased significantly between September 30, 2023 and December 31, 2023, but the payables turnover ratio only increased modestly. This suggests that changes in the volume of purchases are not the primary driver of fluctuations in the payables turnover ratio.
Overall, the accounts payable turnover ratio demonstrates a degree of variability, but generally remains within a manageable range. The observed patterns suggest a dynamic, yet controlled, approach to accounts payable management. Continued monitoring is recommended to identify any emerging trends and ensure optimal supplier relationships.
Working Capital Turnover
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||
| Current assets | |||||||||||||||||||||
| Less: Current liabilities | |||||||||||||||||||||
| Working capital | |||||||||||||||||||||
| Revenues | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Working capital turnover1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Working Capital Turnover, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Working capital turnover
= (RevenuesQ4 2025
+ RevenuesQ3 2025
+ RevenuesQ2 2025
+ RevenuesQ1 2025)
÷ Working capital
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The working capital turnover ratio exhibited a generally declining trend from the first quarter of 2022 through the fourth quarter of 2023, followed by a significant increase and subsequent moderation. This indicates fluctuations in the efficiency with which the company utilizes its working capital to generate revenue.
- Initial Decline (Q1 2022 - Q4 2023)
- The working capital turnover ratio decreased from 0.97 in March 2022 to 0.85 in December 2022, continuing to 0.87 by September 2023. This suggests a decreasing ability to generate sales from each dollar of working capital during this period. The decline could be attributed to increases in working capital outpacing revenue growth, or a slowdown in revenue generation relative to the investment in current assets.
- Significant Increase (Q1 2024 - Q2 2024)
- A substantial increase in the ratio is observed from 0.93 in December 2023 to 1.92 in June 2024. This represents a marked improvement in working capital efficiency, indicating that the company was generating significantly more revenue per dollar of working capital. This jump coincides with a notable decrease in working capital, suggesting a successful reduction in current asset investments or more efficient management of short-term liabilities.
- Moderation and Recent Trend (Q3 2024 - Q2 2025)
- Following the peak in June 2024, the ratio moderated to 1.64 in December 2025. While still elevated compared to the earlier periods, the decrease suggests a stabilization of working capital utilization. The ratio fluctuated between 1.82 and 1.92 in the quarters following the initial surge, before decreasing in the most recent quarter. This suggests that while improvements were made, the exceptionally high efficiency levels seen in the first half of 2024 were not fully sustained.
Overall, the company experienced a period of declining working capital efficiency, followed by a dramatic improvement and a subsequent leveling off. The fluctuations warrant further investigation to understand the underlying drivers of these changes, particularly the factors contributing to the significant increase in the ratio during the first half of 2024 and the subsequent moderation.
Average Inventory Processing Period
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Inventory turnover | |||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||
| Average inventory processing period1 | |||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||
| Average Inventory Processing Period, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The average inventory processing period exhibits a consistent upward trend over the observed timeframe. Initially, the period stood at 129 days in March 2022, and progressively increased to 373 days by March 2025. This indicates a lengthening in the time required to convert inventory into sales.
- Overall Trend
- A clear and sustained increase in the average inventory processing period is evident throughout the period. The rate of increase appears to accelerate over time, with larger absolute changes observed in more recent quarters.
- Phases of Change
- From March 2022 to December 2022, the period increased by 27 days, representing a moderate pace of change. A more substantial increase of 53 days occurred between March 2022 and June 2023. The period then increased by another 71 days between June 2023 and March 2025, demonstrating a significant acceleration in the lengthening of the processing period.
- Recent Performance
- The most recent quarters show the largest increases. The period moved from 287 days in December 2024 to 320 days in March 2025, and then to 345 days in June 2025, before reaching 369 days in September 2025 and finally 373 days in December 2025. This suggests that factors contributing to the extended processing period are becoming more pronounced.
The concurrent decline in inventory turnover, as indicated by the provided figures, supports the observation of a lengthening inventory processing period. A decreasing turnover ratio directly correlates with a longer time to sell inventory.
Average Receivable Collection Period
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Receivables turnover | |||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||
| Average receivable collection period1 | |||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The average receivable collection period exhibited relative stability over the observed period, with some fluctuations. Generally, the period remained within a narrow range, indicating consistent efficiency in collecting receivables. However, a slight upward trend emerged in the latter portion of the analyzed timeframe.
- Overall Trend
- From March 31, 2022, through December 31, 2022, the average collection period fluctuated between 58 and 59 days. A slight increase was noted in the first quarter of 2023, reaching 61 days, before returning to 60 days in the subsequent quarter. The period then decreased to 58 days by September 30, 2023, and remained at 58 days through December 31, 2023. A noticeable increase to 64 days occurred in the first quarter of 2024, followed by a return to 58 days in the second quarter. The period then fluctuated between 60 and 53 days through the remainder of 2024. The final four quarters observed show a gradual increase from 59 days to 62 days.
- Short-Term Fluctuations
- The most significant single-quarter change was an increase of 6 days in the average collection period between December 31, 2023, and March 31, 2024. A decrease of 11 days was observed between September 30, 2024, and December 31, 2024. These fluctuations suggest potential impacts from changes in sales terms, customer payment behavior, or collection efforts during those specific periods.
- Recent Developments
- The most recent four quarters (March 31, 2025 – December 31, 2025) demonstrate a consistent, albeit slight, upward trend in the average collection period, moving from 59 days to 62 days. This warrants further investigation to determine if this represents a developing pattern or a temporary anomaly.
In conclusion, while the average receivable collection period has generally been consistent, the recent trend suggests a potential lengthening of the time required to collect receivables. Continued monitoring is recommended to assess the sustainability of this trend and its potential implications for cash flow.
Operating Cycle
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Average inventory processing period | |||||||||||||||||||||
| Average receivable collection period | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Operating cycle1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Operating Cycle, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =
2 Click competitor name to see calculations.
The operating cycle has demonstrated a consistent lengthening trend over the analyzed period, spanning from March 31, 2022, to December 31, 2025. This indicates that the time required to convert investments in inventory and other resources into cash from sales is increasing. Both components of the operating cycle – the average inventory processing period and the average receivable collection period – contribute to this overall trend, though to differing degrees.
- Average Inventory Processing Period
- The average inventory processing period exhibits a clear upward trajectory. Starting at 129 days in March 31, 2022, it steadily increased to 156 days by December 31, 2022. This growth continued into 2023, reaching 192 days by June 30, 2023, and culminating in 373 days by December 31, 2025. The rate of increase appears to accelerate in the later periods, suggesting a potential shift in inventory management practices or increasing challenges in efficiently converting inventory to sales. The most significant increases occurred between March 31, 2024 and December 31, 2025.
- Average Receivable Collection Period
- The average receivable collection period shows less dramatic fluctuations compared to the inventory processing period, but still demonstrates an overall increasing trend. It began at 59 days in March 31, 2022, and remained relatively stable around 58-61 days through September 30, 2023. A slight increase is observed in March 31, 2024, reaching 64 days, followed by a decrease to 53 days in December 31, 2024, before rising again to 62 days by December 31, 2025. While the fluctuations are present, the period generally trends upward over the entire timeframe.
- Operating Cycle
- As a result of the combined trends in inventory processing and receivable collection, the operating cycle has lengthened from 188 days in March 31, 2022, to 435 days by December 31, 2025. The most substantial increases in the operating cycle align with the periods of most rapid growth in the average inventory processing period. The increase from 340 days in December 31, 2024 to 435 days in December 31, 2025 is particularly noteworthy.
The consistent lengthening of the operating cycle warrants further investigation. Potential contributing factors could include changes in product mix, shifts in customer payment terms, inefficiencies in supply chain management, or an accumulation of obsolete inventory. Understanding the underlying drivers of these trends is crucial for optimizing working capital management and maintaining financial health.
Average Payables Payment Period
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Payables turnover | |||||||||||||||||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||
| Average payables payment period1 | |||||||||||||||||||||
| Benchmarks (no. days) | |||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The average payables payment period exhibited considerable fluctuation throughout the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values indicated a relatively stable period, followed by increased variability and a potential stabilization towards the end of the analyzed timeframe.
- Overall Trend
- The average payables payment period demonstrated a lack of consistent directional movement. While there were periods of increase and decrease, no clear long-term trend emerged. The period began at 66 days, increased to a peak of 117 days, and concluded at 102 days.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- From March 31, 2022, to December 31, 2022, the average payables payment period generally increased. It rose from 66 days to 73 days in the second quarter, then decreased significantly to 44 days before peaking at 103 days by the end of the year. This suggests potential shifts in supplier credit terms or changes in the timing of invoice payments during this period.
- Extended Period (Mar 31, 2023 – Dec 31, 2024)
- The period from March 31, 2023, to December 31, 2024, showed continued volatility. The payment period remained elevated, fluctuating between 85 and 115 days. A slight decrease was observed towards the end of 2024, moving from 98 days to 98 days, indicating a possible return towards more typical payment terms.
- Final Period (Mar 31, 2025 – Dec 31, 2025)
- The final period showed a slight increase followed by stabilization. The average payables payment period increased from 102 days to 105 days, then decreased to 95 days, and finally settled at 102 days by December 31, 2025. This suggests a potential attempt to manage cash flow through extended payment terms, followed by a slight adjustment.
The fluctuations in the average payables payment period warrant further investigation to understand the underlying drivers. Factors such as changes in supplier relationships, negotiation of credit terms, and internal payment processing efficiencies could all contribute to these observed variations.
Cash Conversion Cycle
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||
| Average inventory processing period | |||||||||||||||||||||
| Average receivable collection period | |||||||||||||||||||||
| Average payables payment period | |||||||||||||||||||||
| Short-term Activity Ratio | |||||||||||||||||||||
| Cash conversion cycle1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Cash Conversion Cycle, Competitors2 | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + – =
2 Click competitor name to see calculations.
The short-term operating activity of the company, as measured by its cash conversion cycle and component ratios, demonstrates notable shifts over the observed period. A general trend of lengthening in the cash conversion cycle is apparent, particularly from 2023 onwards. This lengthening is driven by changes in inventory management, accounts receivable collection, and accounts payable payment practices.
- Average Inventory Processing Period
- The average inventory processing period exhibits a consistent upward trend throughout the period. Starting at 129 days in March 2022, it steadily increased to 373 days by December 2025. This suggests a growing inefficiency in managing inventory, potentially indicating increased holding costs, obsolescence risk, or a deliberate strategy to build up inventory levels. The most significant increases occurred between March 2023 and December 2024.
- Average Receivable Collection Period
- The average receivable collection period remained relatively stable between March 2022 and December 2022, fluctuating between 58 and 61 days. A slight increase was observed in early 2023, peaking at 64 days in March 2023, before returning to a range of 58-62 days through December 2025. While generally stable, the slight increase and subsequent fluctuation suggest potential minor variations in the company’s ability to collect payments from customers.
- Average Payables Payment Period
- The average payables payment period demonstrates more volatility than the other two ratios. It began at 66 days in March 2022, increased to 115 days by June 2023, and then decreased to 102 days by December 2025. The peak in June 2023 suggests the company strategically extended its payment terms to suppliers, potentially to improve short-term cash flow. The subsequent decrease indicates a return towards more typical payment practices, though still generally longer than the initial period.
- Cash Conversion Cycle
- The cash conversion cycle increased from 122 days in March 2022 to 333 days by December 2025. This increase is primarily attributable to the lengthening inventory processing period, which outweighs the relatively stable receivable collection period and the fluctuating payables payment period. The most substantial increases in the cash conversion cycle occurred between September 2023 and December 2025, indicating a growing time lag between investing in inventory and converting it into cash. This trend warrants further investigation to determine its impact on liquidity and overall financial health.
In summary, the company’s operating cycle has become significantly longer over the analyzed period. The primary driver of this change is a substantial increase in the time required to process inventory. While payables management has shown some flexibility, it has not been sufficient to offset the impact of slower inventory turnover. Continued monitoring of these trends is recommended.